***Cite this as*:** Chunxiao DAI, Yaoyang FU, Xuanwei LI, Meihua LIN, Yinbo LI, Xiao LI, Keke HUANG, Chengcheng ZHOU, Jian XIE, Qingwei ZHAO, Shaohua HU. Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression[J]. Journal of Zhejiang University Science B, 2025, 26(1): 26-38.
http://doi.org/10.1631/jzus.B2400470

Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression

Key words: Bipolar II depression; Lurasidone; Vortioxetine; Combination

Research Summary

This article mainly focused on the efficacy and safety of vortioxetine(VOR) as an adjuvant drug in bipolar depression in the following aspects:





- **Mean change in the MADRS total score from week 4 to week 12**
- **Incidence of side effects**
- **Risk of switching to mania/hypomania**



Innovation points

- **The first study to evaluate the efficacy and safety of VOR as an adjunctive therapeutic agent combined with Lurasidone (LUR) for bipolar II depression.**
- **Three patients in the vortioxetine group appeared to switch to mania or hypomania.**
- **Evaluate the monotherapy efficacy of LUR in treating bipolar II depression.**
- **No significant correlation between LUR concentration and the MADRS reduction rate.**

Figure 4

Innovation points

A series of comprehensive tables were generated to summarize the results of the study.

Figure 1｜ **Enrolment and randomization.**

Figure 2｜**Changes in the MADRS, HAMD, HAMA, and YMRS scores of the response and no-response groups during LUR monotherapy after 4 weeks of treatment**.

Figure 3｜**Dose (a) and concentration (b) of lurasidone in the response and no-response groups during the 4-week lurasidone monotherapy treatment.**

Figure 4｜**Changes in the MADRS, HAMD, HAMA, and YMRS scores of the valprote (VAL) and VOR groups in phase 2 treatment.**

Table 4｜**Adverse events of the VAL and VOR groups.**